MedTrace Logo

Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris

NCT03806790 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 182

Last updated 2025-03-10

Study results available
· View outcomes & findings →

Summary

Comparison of the efficacy of LEO 90100 foam with Dovobet® ointment in the treatment of psoriasis in Japanese subjects.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

LEO 90100 foam

Once daily topical application of foam from a can to psoriasis lesions. Dose depends on size of lesion.

DRUG

Dovobet® ointment

Once daily topical application of ointment from a tube to psoriasis lesions. Dose depends on size of lesion.

Sponsors & Collaborators

  • LEO Pharma

    lead INDUSTRY

Principal Investigators

  • Medical Expert · LEO Pharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-24
Primary Completion
2019-06-10
Completion
2019-06-10

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03806790 on ClinicalTrials.gov